Beta
Back to EDIT.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

EDIT Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Editas medicine, inc. (EDIT) 2025Q4 financial report shows revenue of 24.74M USD, with a YoY growth rate of -19.16%. This clearly indicates that Editas medicine, inc. (EDIT) is facing severe revenue challenges and a significant deterioration. To better understand the business situation, investors are advised to look beyond the revenue YoY, and closely examine trends in net profit, operating profit, and gross margin. In addition, leveraging third-party data such as Growin AI Value Analysis will provide a more comprehensive assessment of the operational pressure and potential financial risks faced by Editas medicine, inc. (EDIT).